Download PDF
Planta Med 2006; 72(9): 807-813
DOI: 10.1055/s-2006-946638
Original Paper
Pharmacology
© Georg Thieme Verlag KG Stuttgart · New York

Extracts from Pygeum africanum and Other Ethnobotanical Species with Antiandrogenic Activity

Sonja Schleich1 , Maria Papaioannou2 , Aria Baniahmad2 , 3 , Rudolf Matusch1
  • 1Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, Marburg, Germany
  • 2Genetisches Institut, Justus-Liebig-Universität Giessen, Giessen, Germany
  • 3Department of Biochemistry, University Kuopio, Finland
Further Information

Publication History

Received: January 25, 2006

Accepted: April 27, 2006

Publication Date:
19 June 2006 (online)

    Permissions and Reprints

Abstract

Extracts from Pygeum africanum, Serenoa repens and Cucurbita pepo are used in the treatment of benign prostatic hyperplasia (BPH) and prostate cancer (PCa). The activity of the androgen receptor (AR) is known to control growth of the prostate. Here, we examined extracts of these plants for their antiandrogenic activity using an AR responsive reporter gene assay for drug discovery. A selective dichloromethane extract from the stem barks of Pygeum africanum revealed the highest antiandrogenic effect. Bioactivity-directed fractionation of this extract led to the isolation of N-butylbenzenesulfonamide (NBBS) indicating that extracts of the stem bark of P. africanum harbour androgen antagonistic activity. This compound may provide a novel approach for the prevention and treatment of BPH and human PCa.

Abbreviations

AR:human androgen receptor

BPH:benign prostate hyperplasia

C. pep:Cucurbita pepo

IPSS:international prostate symptom score

NBBS:N-butylbenzenesulfonamide

P. africanum:Pygeum africanum

PCa:prostate cancer

QoL:quality of life

R1881:methyltrienolone

RLU:relative light units

S. repens:Serenoa repens

Key words

Antiandrogenic activity - Pygeum africanum - Rosaceae - Serenoa repens - Arecaceae - Cucurbita pepo - Cucurbitaceae - N-butylbenzenesulfonamide - prostate hyperplasia

References

  • 1 Shah U S, Getzenberg R H. Fingerprinting the diseased prostate, associations between BPH and prostate cancer.  J Cell Biochem. 2004;  91 161-9
    CrossrefPubMedGoogle Scholar
  • 2 Levin R M, Das A K. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens .  Urol Res. 2000;  28 201-9
    CrossrefPubMedGoogle Scholar
  • 3 Gonzalgo M L, Isaacs W B. Molecular pathways to prostate cancer.  J Urol. 2003;  170 2444-52
    CrossrefPubMedGoogle Scholar
  • 4 Bombardelli E, Morazzoni P. Prunus Africana (Hook. f.) Kalkm.  Fitoterapia. 1997;  68 205-18
    PubMedGoogle Scholar
  • 5 Andro M C, Riffaud J P. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: A review of 25 year of published experience.  Curr Ther Res Clin Exp. 1995;  56 796-817
    CrossrefPubMedGoogle Scholar
  • 6 Yablonsky F, Nicolas V, Riffaud J P, Bellamy F. Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts.  J Urol. 1997;  157 2381-7
    CrossrefPubMedGoogle Scholar
  • 7 Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension.  Urology. 1999;  54 473-8
    CrossrefPubMedGoogle Scholar
  • 8 Ishani A, MacDonald R, Nelson D, Rutks I, Wilt T J. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis.  Am J Med. 2000;  109 654-64
    CrossrefPubMedGoogle Scholar
  • 9 Dreikorn K. The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia.  World J Urol. 2002;  19 426-35
    PubMedGoogle Scholar
  • 10 Breza J, Dzurny O, Borowka A, Hanus T, Petrik R, Blane G. et al . Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe.  Curr Med Res Opin. 1998;  14 127-39
    PubMedGoogle Scholar
  • 11 Bombardelli E, Morazzoni P. Serenoa repens (Bartram) J.K. Small.  Fitoterapia. 1997;  68 99-113
    PubMedGoogle Scholar
  • 12 Al-Shukri S H, Deschaseaux P, Kuzmin I V, Amdiy R R. Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (Permixon®) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.  Prostate Cancer Prostatic Dis. 2000;  3 195-9
    CrossrefPubMedGoogle Scholar
  • 13 Gerber G S, Kuznetsov D, Johnson B C, Burstein J D. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms.  Urology. 2001;  58 960-4
    CrossrefPubMedGoogle Scholar
  • 14 Debruyne F, Koch G, Boyle P, Da Silva F C, Gillenwater J G, Hamdy F C. et al . Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.  Eur Urol. 2002;  41 497-507
    CrossrefPubMedGoogle Scholar
  • 15 Bombardelli E, Morazzoni P. Cucurbita pepo L.  Fitoterapia. 1997;  68 291-302
    PubMedGoogle Scholar
  • 16 Longo R, Tira S. Constituents of Pygeum africanum Bark.  Planta Med. 1981;  42 195-6
    PubMedGoogle Scholar
  • 17 McClure M W. An overview of holistic medicine and complementary and alternative medicine for the prevention and treatment of BPH, prostatitis, and prostate cancer.  World J Urol. 2002;  20 273-84
    CrossrefPubMedGoogle Scholar
  • 18 Awad A B, Burr A T, Fink C S. Effect of resveratrol and beta-sitosterol in combination on reactive oxygen species and prostaglandin release by PC-3 cells.  Prostaglandins Leukot Essent Fatty Acids. 2005;  72 219-26
    CrossrefPubMedGoogle Scholar
  • 19 Kim K K, Kang J G, Moon S, Kang K Y. Isolation and identification of antifungal N-butylbenzensulfonamide produces by Pseudomonas sp. AB2.  J Antibiot. 2000;  53 131-6
    PubMedGoogle Scholar
  • 20 Gast A, Schneikert J, Cato A C. N-terminal sequences of the human androgen receptor in DNA binding and transrepressing functions.  J Steroid Biochem Mol Biol. 1998;  65 117-23
    CrossrefPubMedGoogle Scholar
  • 21 Dotzlaw H, Moehren U, Mink S, Cato A C, Iniguez Lluhi J A, Baniahmad A. The amino terminus of the human AR is target for corepressor action and antihormone agonism.  Mol Endocrinol. 2002;  16 661-73
    CrossrefPubMedGoogle Scholar
  • 22 Dotzlaw H, Papaioannou M, Moehren U, Claessens F, Baniahmad A. Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor.  Mol Cell Endocrinol. 2003;  213 79-85
    CrossrefPubMedGoogle Scholar
  • 23 Fourneau C, Hocquemiller R, Cavé A. Triterpenes from Prunus africana bark.  Phytochemistry. 1996;  42 1387-89
    CrossrefPubMedGoogle Scholar
  • 24 Bach D. Placebokontrollierte Langzeittherapiestudie mit Kürbissamenextrakt bei BPH-bedingten Miktionsbeschwerden.  Urologe B. 2000;  40 437-43
    CrossrefPubMedGoogle Scholar
  • 25 Klippel K P, Hiltl D M, Schipp B, the German BPHP study g roup. Randomized double-blinded placebo controlled trial to evaluate the efficacy of β-sitosterol (phytosterol) in patients with obstructive and irritative symptoms due to BPH.  Brit J Urol. 1997;  80 427-32
    PubMedGoogle Scholar
  • 26 Schleich S, Papaioannou M, Baniahmad A, Matusch R. Activity-guided isolation of an antiandrogenic compound of Pygeum africanum. Planta Med, in press
    Google Scholar
  • 27 Huppert N, Würtele M, Hahn H H. Determination of the plasticizer N-butylbenzenesulfonamide and the pharmaceutical Ibuprofen in wastewater using solid phase microextraction (SPME).  Fresenius J Anal Chem. 1998;  362 529-36
    CrossrefPubMedGoogle Scholar
  • 28 Poliakova O V, Lebedev A T, Hänninen O. Organic pollutants in snow of urban and rural Russia and Finland.  Environ Toxicol Chem. 2000;  75 181-94
    PubMedGoogle Scholar

Aria Baniahmad

Institute of Human Genetics and Anthropology

University of Jena

Kollegiengasse 10

07745 Jena

Germany

Phone: +49-3641-935-524

Fax: +49-3641-934-706

Email: aban@mti.uni-jena.de

      >